Lexiva (fosamprenavir calcium) Tablets and Oral Suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

Summary View

Sections Modified

DRUG INTERACTIONS

• Table 6: Established and Other Potentially Significant Drug Interactions
  • Narcotic analgesic
    • Methadone
      • Data suggest that the interaction is not clinically relevant; however, patients should be monitored for opiate withdrawal symptoms.